Do you know the current revenue numbers and what percentage of the CF market Novartis currently owns? I didn't think so.
The podinhaler is and will remain the first tier drug of choice in a rotational regime.before you start putting up nonsense do some due diligence.
Novartis has a superior drug in availability in price and in outreach in markets throughout the world for the next decade when all antibiotics will be replaced by newer technologies.Novartis is not interested in amother small player in the CF market.Arikace is just that
NO.It is common not to talk about the earnings. Insmed is hiding behind that.They will not discuss the obvious flaw in the trial protocol which has nothing to do with the companys financial situation.
TOBI is a far better drug than Arikace.once a day is no big adv.Price and a big pharma will make Arikace a wannabe
and dominates the CF market and will do so for many years. Insmeds entry in Europe will be a very small revenue base.If Insmed achieves revenues from CF by 2019 of over 25 million,everyone will be surprised.the novartis post is for idiots who need info.You assume approval.EU may want to wait for more data
If there was no problem the company would have released the mITT data.They didn't so many think there is a problem and not just honk honk oink whistles Cramers crew.
The secondary endpoint does not have to be disclosed.It is important. Insmed is hiding something.
Be afraid,be very afraid.